Get all premium features to the best stock analysis tool

A new product introduction helped lift the top line. It seems there's more where that came from, with new product introductions scheduled over the coming months.

MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.

MiniMed Group Inc (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.

MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript

MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.

Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organic Advanced global pipeline ahead of schedule with FDA submission for MiniMed Fit™, CE Mark for MiniMed Flex™, Vivera™ FCL U.S. pivotal trial enrollment completion, and IDE approval for next-gen extended wear MiniMed sensor Raises fiscal year 2027 organic revenue growth guidance NORTHRIDGE, Calif., Sept. 1, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its first quarter (Q1) of fiscal year 2027 (FY27), ended July 31, 2026.

MiniMed Group, Inc. (NASDAQ:MMED) will release its first quarter earnings report before the opening bell on Tuesday, Sept. 1.